Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26126284 | 1.00 | ITGB3 (0.44) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL541261 | 1.00 | ITGB3 (0.44) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL7893552 | 0.97 | ITGB3 (0.47) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL7257726 | 0.96 | ITGB3 (0.48) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| Methoxymethane SCHEMBL2940968 | 0.95 | ITGB3 (0.46) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL7887537 | 0.95 | ITGB3 (0.50) | ITGB3ITGA2BSLC15A2SLC6A5 | |
| SCHEMBL4653518 | 0.95 | ITGB3 (0.50) | ITGB3ITGA2BSLC15A2SLC6A5 | |
| SCHEMBL8630043 | 0.95 | ITGB3 (0.50) | ITGB3ITGA2BSLC15A2SLC6A5 | |
| Carnosine SCHEMBL33768 | 0.92 | ITGB3 (0.41) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| Carnosine SCHEMBL3904964 | 0.92 | ITGB3 (0.41) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328409-B1 | COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION | METIS HEALTHCARE S R L (IT) | 2023-08-23 | — | — | EP | claimed |
| WO-2023139414-A1 | COMPOSITION FOR TREATING ESOPHAGEAL REFLUX | METIS HEALTHCARE S.R.L. (IT) | 2023-07-27 | — | — | WO | claimed |
| US-10646476-B2 | Method for treatment of humoral secretion dysfunctions | METIS HEALTHCARE S.R.L. (IT) | 2020-05-12 | — | — | US | claimed |
| US-20180207134-A1 | COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION | METIS HEALTHCARE S.R.L. (IT) | 2018-07-26 | — | — | US | claimed |
| EP-4469034-A1 | COMPOSITION FOR TREATING ESOPHAGEAL REFLUX | Metis Healthcare S.r.L. (IT) | 2024-12-04 | — | — | EP | disclosed |
| US-12083204-B2 | Topical composition for homeostatic delivery of nitric oxide and uses thereof | L'OREAL (FR) | 2024-09-10 | — | — | US | disclosed |
| WO-2023233383-A2 | TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOF | L'OREAL (FR) | 2023-12-07 | — | — | WO | disclosed |
| US-20230390172-A1 | TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOF | Dermaforce Holdings, LLC | 2023-12-07 | — | — | US | disclosed |
| WO-2023188173-A1 | AGENT FOR INCREASING INTRACEREBRAL GABA | 日本ハム株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-3328409-B1 | COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION | METIS HEALTHCARE S R L (IT) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023139414-A1 | COMPOSITION FOR TREATING ESOPHAGEAL REFLUX | METIS HEALTHCARE S.R.L. (IT) | 2023-07-27 | — | — | WO | disclosed |
| CN-115024997-A | Cosmetic composition with skin aging resisting effect | 彭氏(惠州)实业发展有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3118211-A1 | AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2017-01-18 | — | — | EP | disclosed |
| US-20160271109-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | ANTEIS SA (CH) | 2016-09-22 | — | — | US | disclosed |
| US-9375398-B2 | Peptides for skin rejuvenation and methods of using the same | NEOCUTIS S.A. (CH) | 2016-06-28 | — | — | US | disclosed |
| EP-2970382-A2 | PEPTIDES FOR SKIN REJUVENATION AND METHODS OF USING THE SAME | Neocutis SA (CH) | 2016-01-20 | — | — | EP | disclosed |
| CN-102448992-B | Stabilizing composition for immobilized biomolecules | LEUKOCARE AG | 2015-06-10 | — | — | CN | disclosed |
| US-20140309173-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | ANTEIS SA (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2014140890-A2 | PEPTIDES FOR SKIN REJUVENATION AND METHODS OF USING THE SAME | NEOCUTIS SA (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-4529602-A | Sulfodehydroabietic acid compound | TANABE SEIYAKU CO., LTD. (JP) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271109-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | CUTA, PLOD3, MMP13 | ITGB3 3504/4885ITGA2B 3943/4885SLC15A2 1358/4885 |
| US-20140309173-A1 | Peptides For Skin Rejuvenation And Methods Of Using The Same | CUTA, PLOD3, MMP13 | ITGB3 3504/4885ITGA2B 3943/4885SLC15A2 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.